China's Hutchison MediPharma Phase IIb Trials In Ulcerative Colitis Meet Primary, Secondary Endpoints
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Chinese biotech Hutchison MediPharma announced Nov. 5 that its Phase IIb global clinical trial of lead candidate HMPL-004 in patients with ulcerative colitis, a form of inflammatory bowel disease, met primary and key secondary endpoints
You may also be interested in...
A Closer Look: Hutchison MediTech TCM Deal With Nestle Reaches Into Pharma Development
A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&D firm’s long search for a partner.
Chi-Med Expected To Double Revenue By 2015, Backed By Urbanization, Healthcare Reform And TCM Performance in China
SHANGHAI - UK-listed Chinese healthcare company Chi-Med is expected to double its current revenues of $111 million in the next five years, backed by rapid growth in traditional Chinese medicine and consumer products, U.S. investment banking firm Piper Jaffray said in an Aug. 4 research note
Chi-Med Expected To Double Revenue By 2015, Backed By Urbanization, Healthcare Reform And TCM Performance in China
SHANGHAI - UK-listed Chinese healthcare company Chi-Med is expected to double its current revenues of $111 million in the next five years, backed by rapid growth in traditional Chinese medicine and consumer products, U.S. investment banking firm Piper Jaffray said in an Aug. 4 research note